Companies › Shanghai UniXell Biotechnology
3 active drug programs in 3 registered trials: 3 Phase 1; Neurology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| UX-DA001 Human midbrain dopaminergic progenitor cells that differentiate into mature dopaminergic n | – | Phase 1 | Parkinson Disease, Idiopathic | Dec 2027 |
| UX-GIP001 Allogeneic human GABAergic interneuron precursor cells | – | Phase 1 | Epilepsy | Jul 2029 |
| UX-DA003 Human allogeneic iPSC-derived midbrain dopaminergic progenitor cells | – | Phase 1 | Parkinson's Disease | Aug 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06778265 | UX-DA001 | Phase 1 | Parkinson Disease, Idiopathic | Neurology | Dec 2027 |
| NCT07572812 | UX-GIP001 | Phase 1 | Epilepsy | Neurology | Jul 2029 |
| NCT07733349 | UX-DA003 | Phase 1 | Parkinson's Disease | Neurology | Aug 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.